Lista de obras - Emir Hadzijusufovic - Dominio Público Uruguay

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

artículo científico publicado en 2012

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML

scientific article published on 28 December 2018

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

artículo científico publicado en 2014

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis

artículo científico publicado en 2021

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

artículo científico publicado en 2014

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms

artículo científico publicado en 2019

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

artículo científico publicado en 2017

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells

scientific article published on 13 August 2019

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

artículo científico publicado en 2012

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia

artículo científico publicado en 2017

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

artículo científico publicado en 2009

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)

artículo científico publicado en 2013

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

artículo científico publicado en 2010

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

artículo científico publicado en 2016

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

artículo científico publicado en 2015

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

artículo científico publicado en 2014

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

artículo científico publicado en 2015

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells

artículo científico publicado en 2020

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

artículo científico publicado en 2010

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

artículo científico publicado en 2011

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

scientific article published on 13 July 2018

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

artículo científico publicado en 2012

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

artículo científico publicado en 2017

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

scientific article published on 29 January 2014

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

artículo científico publicado en 2010

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

artículo científico publicado en 2011

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders

artículo científico publicado en 2017

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

artículo científico publicado en 2017

STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms

artículo científico publicado en 2020

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

artículo científico publicado en 2007

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

artículo científico publicado en 2013

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML

artículo científico publicado en 2017

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

artículo científico publicado en 2016

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

artículo científico publicado en 2008

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

artículo científico publicado en 2018

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

artículo científico publicado en 2017

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

artículo científico publicado en 2014

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

artículo científico publicado en 2018

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

artículo científico publicado en 2012

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

artículo científico publicado en 2013

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

artículo científico publicado en 2014

Lista de obras de Emir Hadzijusufovic

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. ⬇️

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.